N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 4 N=81 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Frontal Lobe Dementia · Frontotemporal Lobe Dementia · Semantic Dementia
Primary: Change in Neuropsychiatric Inventory (NPI) — -1.9; 0.3 units on a scale
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 3 N=387 A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Alzheimer's Disease
Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants
Phase 2 N=27 Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's Disease
Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05
Phase 2 N=46 Dapagliflozin In Alzheimer's Disease
Alzheimer Disease
Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Phase 2 N=31 Memory and Insulin in Early Alzheimer's Disease
Alzheimer's Disease
Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels
N/A N=10 Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Phase 1 N=106 A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
Alzheimer's Disease
Primary: Change in Mean Computer-based Cognitive Assessment (CogState) Composite Score at Week 4 — -0.10; -0.07 Score on a scale — p=0.231
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=14,442 A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease
Alzheimer Disease
Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
Phase 2 N=71 Imaging Tau in Alzheimer's Disease and Normal Aging
Alzheimer Disease
Primary: 18F-MK-6240 Binding — 1.41; 2.30 SUVr
N/A N=10 tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
Phase 2 N=28 Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
Alzheimer's Disease
Primary: Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With…
N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Phase 2 N=65 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Alzheimer's Disease · Healthy Non-elderly and Elderly Adults
Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants
Phase 4 N=12 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
Alzheimer Disease
Primary: Changes in the Metabolite Ratios of N-acetylaspartate (NAA) to Creatine (Cr), Myo-inositol (mI) to Cr, Choline (Cho) to Cr, NAA to Cho, and NAA to mI, on Cholinesterase…
Phase 1 N=145 Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
Alzheimer Disease
Primary: Regional SUVR Value for 18F-MK-6240 — 1.27 SUVR
N/A N=42 Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
Phase 3 N=223 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Alzheimer's Disease
Primary: Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline — 36; 31; 27; 37 Participants — p=0.067